{"text": ["Sandoz", "submits", "Biologics", "License", "Application", "for", "proposed", "biosimilar", "trastuzumab", "to", "US", "FDA"], "created_at": "2021-12-20 21:05:00"}
{"text": ["Market", "check:", "Stocks", "open", "lower,", "yield", "curve", "steepens,", "oil", "under", "pressure"], "created_at": "2021-12-20 15:15:59"}
{"text": ["Novartis", "Inks", "Option", "Agreement", "For", "BeiGene", "Anti-Cancer", "Therapy", "For", "Over", "$1B"], "created_at": "2021-12-20 14:02:01"}
{"text": ["Novartis'", "Ligelizumab", "Suffers", "Setback", "In", "Late-Stage", "Skin", "Disorder", "Studies"], "created_at": "2021-12-20 12:22:10"}
{"text": ["BeiGene", "to", "receive", "up", "to", "$1", "billion", "in", "oncology", "deal", "with", "Novartis"], "created_at": "2021-12-20 11:25:58"}
{"text": ["Novartis", "strengthens", "immunotherapy", "pipeline", "with", "option,", "collaboration", "and", "license", "agreement", "with", "BeiGene", "for", "TIGIT", "inhibitor", "ociperlimab"], "created_at": "2021-12-20 11:15:00"}
{"text": ["Novartis", "provides", "an", "update", "on", "Phase", "III", "ligelizumab", "(QGE031)", "studies", "in", "chronic", "spontaneous", "urticaria", "(CSU)"], "created_at": "2021-12-20 06:15:00"}
